Dr. Stephanie Goff on Low-Dose Chemotherapy with CAR T-Cells in Advanced Lymphoma

Stephanie Goff, MD
Published Online: Wednesday, Jul 27, 2016


Stephanie Goff, MD, senior staff clinician, National Cancer Institute (NCI), discusses the use of chemotherapy with anti-CD19 CAR T-cells for the treatment of advanced lymphoma.
 
A study investigating high-dose chemotherapy with anti-CD19 CAR T-cells found that the combination induced 4 out of 7 complete response (CR) in patients with advanced lymphoma. However, there was concern that the responses were caused by the chemotherapy and not by the CAR T-Cells, says Goff.
 
A new study was initiated to treat 22 patients with advanced lymphoma with anti-CD19 CAR T-cells and low-dose chemotherapy. Of those patients, 11 had complete responses. The responses have lasted from 6 to 22 months and all are ongoing. There were 19 patients included with diffuse large B-cell lymphoma, 8 of which saw a response.
 
There was an increase in neurotoxicity with the low-dose of chemotherapy. However, this toxcity, while it can appear extreme, goes away in a few weeks. said Goff. 
 

Stephanie Goff, MD, senior staff clinician, National Cancer Institute (NCI), discusses the use of chemotherapy with anti-CD19 CAR T-cells for the treatment of advanced lymphoma.
 
A study investigating high-dose chemotherapy with anti-CD19 CAR T-cells found that the combination induced 4 out of 7 complete response (CR) in patients with advanced lymphoma. However, there was concern that the responses were caused by the chemotherapy and not by the CAR T-Cells, says Goff.
 
A new study was initiated to treat 22 patients with advanced lymphoma with anti-CD19 CAR T-cells and low-dose chemotherapy. Of those patients, 11 had complete responses. The responses have lasted from 6 to 22 months and all are ongoing. There were 19 patients included with diffuse large B-cell lymphoma, 8 of which saw a response.
 
There was an increase in neurotoxicity with the low-dose of chemotherapy. However, this toxcity, while it can appear extreme, goes away in a few weeks. said Goff. 
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Assessing the Clinical Potential for Immunotherapies in the Treatment of Breast CancerFeb 22, 20171.0
Cancer Summaries and Commentaries™: Updates from Singapore: Advances in Personalized Lung Cancer TreatmentFeb 28, 20171.5
Publication Bottom Border
Border Publication